Anne S Tsao
ECOG-ACRIN Cancer Research Group · M.D. Anderson Cancer Center · SWOG Cancer Research Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anne S Tsao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06357988 · Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm · principal investigator
- Ph1NCT04013542 · Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerM.D. Anderson Cancer Center · active not recruiting · ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma · principal investigator
- Ph2NCT03694002 · Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by SurgerySWOG Cancer Research Network · completed · Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma · principal investigator
- Ph1NCT03295227 · Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic CancerM.D. Anderson Cancer Center · recruiting · Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8 · principal investigator
- Ph1NCT03228537 · Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaNational Cancer Institute (NCI) · active not recruiting · Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7 · principal investigator
- Ph2NCT03007030 · Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryM.D. Anderson Cancer Center · active not recruiting · CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma · principal investigator
- Ph2NCT02293005 · Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaM.D. Anderson Cancer Center · completed · Lung Cancer, Mesothelioma · principal investigator
- Ph2NCT01083589 · Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)M.D. Anderson Cancer Center · completed · Non-small Cell Lung Cancer · study chair
- Ph1/Ph2NCT01064648 · Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaNational Cancer Institute (NCI) · active not recruiting · Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma · principal investigator
- Ph1NCT00652574 · Dasatinib in Resectable Malignant Pleural MesotheliomaM.D. Anderson Cancer Center · completed · Malignant Pleural Mesothelioma · principal investigator
- Ph2NCT00485485 · Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell CancerM.D. Anderson Cancer Center · completed · Head and Neck Cancer, Squamous Cell Cancer · principal investigator
- Ph2NCT00410189 · BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLCM.D. Anderson Cancer Center · completed · Lung Cancer · principal investigator
- Ph1NCT00402766 · Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant MesotheliomaM.D. Anderson Cancer Center · completed · Mesothelioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2026 · $926,653 awarded in 2026Same name and institution; not confirmed by an ID
- UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)U10CA180858 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 · $1,267,600 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT06357988
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013Named on NCT01064648
- NCI NCTN- Network Lead Academic Participating Site: USCU10CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Anthony Boutros El-Khoueiry, HEINZ JOSEF LENZ, DAVID IAN QUINN · fiscal years 2014 to 2018Named on NCT01064648
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:00 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- 1,090 citationsRCR 44.6
- 1,015 citationsRCR 56.5
- 936 citationsRCR 31.8
- 567 citationsRCR 26.2
- 339 citationsRCR 10.2
- 248 citationsRCR 15.0
- 213 citationsRCR 14.3
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.Cancer Discov · 2021192 citationsRCR 9.2
- Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.Cancer Prev Res (Phila) · 2009173 citationsRCR 5.1
- 166 citationsRCR 4.6